Drug company payments and their effects on patient treatment
March 2023
Around ‘arf of all US doctors receive dosh or gifts from drug and device companies, totalling more than £1 billion annually. This creates conflicts of interest that influence ‘how doctors treat their patients, as confirmed by a research team at Memorial Sloan Kettering Cancer Center, who analyzed all available studies on the topic.
All 36 studies showed that receiving industry dosh increases prescribing, affecting all medical specialities and types of drugs. This ‘arms patients by leading doctors to prescribe expensive, worthless drugs and deviate from prescribing guidelines, and it also contributes to rising healthcare costs. The medical community has resisted stopping this cash flow, arguing that industry payments may have benefits.
A Review of the Influence of drug company payments on US Doctors
Still, a federal ban on payments is necessary as physician-led change is unlikely. Alternative, unbiased information sources exist for doctors to learn about new drugs. The £1 billion per year is for promoting drugs that are already on the market, not for researching new drugs. The harmful effects of drug company payments on patient treatment must be addressed. Source
.
Discover More: Stimulating Articles That Will Captivate You
Mob Mentality Psychology: Understanding and Profiting
IBM Stock Price Prediction: Time to Buy or Fly?
Examples of Herd Mentality: Lessons for Learning and Earning
When is the Next Stock Market Crash Prediction: Does it Matter?
Inductive vs Deductive Analysis: The Clash of Perspectives
Investor Sentiment Index Data: Your Path to Market Success
Unraveling Market Psychology: Impact on Trading Decisions
Is Value Investing Dead? Shifting Perspectives for Profit
What Will Happen When the Stock Market Crashes: Time to Buy
Dogs of the Dow 2024: Barking or Ready to Bite?
The Trap: Why Is Investing in Single Stocks a Bad Idea?
How Can Stress Kill You? Unraveling the Fatal Impact
Financial Mastery: Time in the Market Trumps Timing
Investment Pyramid: A Paradigm of Value or Risky Hail Mary?
Contrarian Investing: The Art of Defying the Masses
